So here's a classic market story: a big, established player decides to move into a hot new space, and the smaller, specialized companies that were there first suddenly look a lot less special. That's what's happening Tuesday with Hims & Hers Health Inc. (HIMS). Its stock is trading lower after Amazon.com Inc. (AMZN) decided to get into the GLP-1 weight loss drug business in a serious way.
Amazon introduced what it's calling a "GLP-1 Management Program" through its Amazon One Medical service. The idea is pretty straightforward: simplify the whole process of getting obesity treatment by putting primary care, pharmacy services, and virtual care all in one place. If you've ever tried to navigate insurance, doctor's appointments, and pharmacy pickups for a medication, you can see the appeal. Amazon is essentially trying to be the one-stop shop.
This is a direct shot across the bow of Hims & Hers, which operates a health and wellness platform and, notably, offers GLP-1 drugs and care for weight loss. Back in March, Hims & Hers announced it had a deal to make a broad assortment of Novo Nordisk A/S's (NVO) FDA-approved GLP-1 medications available, including the Wegovy pill. It was a big move for the company. Now, Amazon is showing up with its own program, and it's bringing its massive logistics and customer service engine with it.
Amazon's Play: Convenience, Price, and Scale
The heart of Amazon's new initiative is Amazon Pharmacy. It's offering transparent pricing and delivery for these medications. The platform includes newly FDA-approved oral treatments like Wegovy and Eli Lilly and Co.'s (LLY) Foundayo. The pricing structure is designed to be simple: if you use insurance, it can start as low as $25 per month. If you're paying cash, options start from $149.
For injectable options—including Wegovy, Zepbound auto-injector, and KwikPen—prices start at $299 per month. And of course, this is Amazon, so delivery is a key part of the pitch. Medications can be delivered nationwide, with same-day delivery currently available in nearly 3,000 locations. The company expects to expand that to 4,500 locations by 2026.
Customers can compare insurance and cash prices right at checkout, with any eligible discounts applied automatically. Amazon says its pharmacy customers have already saved more than $200 million through its coupon program. It's the classic Amazon play: use scale and technology to make things easier and cheaper for the customer.
This launch comes as the makers of these drugs are also trying new models. In March, Novo Nordisk introduced a multi-month subscription program for Wegovy. That program is initially being offered through telehealth providers like Ro, WeightWatchers, and LifeMD Inc (LFMD), with platforms such as Hims & Hers and Sesame expected to join later. So the competitive landscape is getting more crowded from both the supplier and distributor sides.
How It Works for Patients
The new Amazon program is available now at Amazon One Medical locations across the U.S. If you're enrolled, you get your prescription renewals through your primary care provider there.
But what if you're already on a GLP-1 medication and you're not in the One Medical network? Amazon has a solution for that, too. It's offering 24/7 telehealth renewal services. A messaging consultation will run you $29, and a video visit is $49. The company is careful to note that this is just for renewals—it doesn't support getting a brand-new prescription. It's a way to capture existing users who might want a more convenient renewal process.
The market reaction was swift. Hims & Hers shares were down 5.42% at $29.34 at the time of publication on Tuesday. When Amazon decides to compete in your space, investors tend to get nervous. It's not just about the specific service; it's about the sheer resources and customer reach Amazon can bring to bear.
For now, the story is about price pressure and competitive fears. But the bigger picture is about how healthcare delivery is changing. Companies are racing to build integrated platforms that make it easier for patients to get the new, effective—but often complex and expensive—treatments like GLP-1s. Amazon just made that race a lot more interesting.
.jpeg)
